Literature DB >> 16705606

Biofilm related infections: is there a place for conservative treatment of port-related bloodstream infections?

J L del Pozo1, A Serrera, A Martinez-Cuesta, J Leiva, J Penades, I Lasa.   

Abstract

Vascular catheters are the most frequently used indwelling medical devices and have become necessary tools for patients with chronic or critical illness. Surgically or percutaneously placed venous access ports are used to facilitate long-term intravenous therapy. The widespread use of these devices has resulted in a dramatic increase in catheter-related infections. It implies considerable morbidity, occasional mortality, and an increase in medical costs derived from its diagnosis, treatment, and mainly, prolongation of the patient's in-hospital stay. Treatment of such infections is often difficult due to the presence of biofilms on the port inner surface; inside the biofilms, bacteria are less vulnerable to antimicrobial agents. Current diagnostic strategies are suboptimal, and most successful treatment options require removal of the infected device followed by a course of antimicrobial therapy. There are limited data concerning the efficacy of antibiotic treatment of port-related bloodstream infections without catheter removal.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16705606     DOI: 10.1177/039139880602900407

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN: 0391-3988            Impact factor:   1.595


  2 in total

1.  A new approach for the discovery of antibiotics by targeting non-multiplying bacteria: a novel topical antibiotic for staphylococcal infections.

Authors:  Yanmin Hu; Alireza Shamaei-Tousi; Yingjun Liu; Anthony Coates
Journal:  PLoS One       Date:  2010-07-27       Impact factor: 3.240

2.  A rat model of central venous catheter to study establishment of long-term bacterial biofilm and related acute and chronic infections.

Authors:  Ashwini Chauhan; David Lebeaux; Benoit Decante; Irene Kriegel; Marie-Christine Escande; Jean-Marc Ghigo; Christophe Beloin
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.